0HB0.LAgios Pharmaceuticals, Inc.

Über

Agios Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of treatments within cellular metabolism and associated biological domains. Its lead product, PYRUKYND (mitapivat), serves as an activator for both healthy and various mutated forms of the pyruvate kinase (PK) enzyme, targeting the management of hemolytic anemias. Additionally, AG-946, an investigational compound, is currently undergoing Phase I clinical evaluation for hemolytic anemias and other conditions. Established in 2007, Agios Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.

www.agios.com

Kennzahlen

Marktkapitalisierung

2.22B

EPS

-7.12

Dividendenrendite

0.00%

Beta

0.59

KBV

1.32

EK-Rendite

-34.6%

Sektor

Healthcare

Branche

Biotechnology

CEO

Brian Goff

Mitarbeiter

486

IPO-Datum

2018-01-29

Land

US